

Lydia Gaba

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5697014/publications.pdf>

Version: 2024-02-01

29
papers

1,435
citations

840585

11
h-index

677027

22
g-index

31
all docs

31
docs citations

31
times ranked

3359
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical implications of the intrinsic molecular subtypes of breast cancer. <i>Breast</i> , 2015, 24, S26-S35.	0.9	735
2	Immune-Related Gene Expression Profiling After PD-1 Blockade in Nonâ€“Small Cell Lung Carcinoma, Head and Neck Squamous Cell Carcinoma, and Melanoma. <i>Cancer Research</i> , 2017, 77, 3540-3550.	0.4	327
3	Rechallenge with BRAF-directed treatment in metastatic melanoma: A multi-institutional retrospective study. <i>European Journal of Cancer</i> , 2018, 91, 116-124.	1.3	69
4	TMPRSS2-ERG in Blood and Docetaxel Resistance in Metastatic Castration-resistant Prostate Cancer. <i>European Urology</i> , 2016, 70, 709-713.	0.9	63
5	Nuclear IGF-1R predicts chemotherapy and targeted therapy resistance in metastatic colorectal cancer. <i>British Journal of Cancer</i> , 2017, 117, 1777-1786.	2.9	58
6	Prognostic implications of genotyping and p16 immunostaining in HPV-positive tumors of the uterine cervix. <i>Modern Pathology</i> , 2020, 33, 128-137.	2.9	23
7	Molecular profiling of peripheral blood is associated with circulating tumor cells content and poor survival in metastatic castration-resistant prostate cancer. <i>Oncotarget</i> , 2015, 6, 10604-10616.	0.8	21
8	Evaluation of an individualized starting-dose of niraparib in the PRIMA/ENGOT-OV26/GOG-3012 study.. <i>Journal of Clinical Oncology</i> , 2020, 38, 6050-6050.	0.8	20
9	Motor polyradiculopathy during pembrolizumab treatment of metastatic melanoma. <i>Muscle and Nerve</i> , 2017, 56, E162-E167.	1.0	18
10	Changes in blood eosinophilia during anti-PD1 therapy as a predictor of long term disease control in metastatic melanoma.. <i>Journal of Clinical Oncology</i> , 2015, 33, 9069-9069.	0.8	15
11	Comparison of HE4, CA125, ROMA and CPH-I for Preoperative Assessment of Adnexal Tumors. <i>Diagnostics</i> , 2022, 12, 226.	1.3	14
12	A first-in-human phase I/Ib dose-escalation clinical trial of the autophagy inducer ABTL0812 in patients with advanced solid tumours. <i>European Journal of Cancer</i> , 2021, 146, 87-94.	1.3	12
13	SEOM-GEICO clinical guidelines on endometrial cancer (2021). <i>Clinical and Translational Oncology</i> , 2022, 24, 625-634.	1.2	11
14	Outcomes after neoadjuvant treatment with gemcitabine and erlotinib followed by gemcitabineâ€“erlotinib and radiotherapy for resectable pancreatic cancer (GEMCAD 10-03 trial). <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 82, 935-943.	1.1	10
15	Efficacy and safety of trabectedin in metastatic uterine leiomyosarcoma: A retrospective multicenter study of the Spanish ovarian cancer research group (GEICO). <i>Gynecologic Oncology Reports</i> , 2020, 33, 100594.	0.3	10
16	Life-threatening colitis and complete response with ipilimumab in a patient with metastatic BRAF-mutant melanoma and rheumatoid arthritis. <i>ESMO Open</i> , 2016, 1, e000032.	2.0	7
17	Association of the Lung Immune Prognostic Index with Immunotherapy Outcomes in Mismatch Repair Deficient Tumors. <i>Cancers</i> , 2021, 13, 3776.	1.7	5
18	AGO-OVAR 28/ENGOT-ov57: Niraparib versus niraparib in combination with bevacizumab in patients with carboplatin-taxane based chemotherapy in advanced ovarian cancerâ€“A multicenter, randomized, phase III trial.. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS5612-TPS5612.	0.8	5

#	ARTICLE	IF	CITATIONS
19	Dose-escalation of the first-in human phase I/II study of ABTL0812, a novel antitumor drug inhibiting the Akt/mTOR pathway in patients with advanced solid tumors.. Journal of Clinical Oncology, 2015, 33, 2585-2585.	0.8	4
20	Encephalitis Associated With Immune Checkpoint Inhibitor Treatment in Patients With Melanoma. Journal of Immunotherapy, 2021, 44, 204-207.	1.2	2
21	Genetic profiling across multiple cancer types using molecular prescreening comprehensive gene panels offered by clinical trials (CT).. Journal of Clinical Oncology, 2021, 39, 3060-3060.	0.8	0
22	ADAGIO: A phase IIb, open-label, single-arm, multicenter study assessing the efficacy and safety of adavosertib (AZD1775) as treatment for recurrent or persistent uterine serous carcinoma.. Journal of Clinical Oncology, 2021, 39, TPS5612-TPS5612.	0.8	0
23	Unscheduled visits in cancer patients treated in a clinical trials unit (CTU).. Journal of Clinical Oncology, 2013, 31, e17580-e17580.	0.8	0
24	Clinical outcomes in BRAFV600-mutant metastatic melanoma with sequential treatment with immunotherapy and BRAF inhibitors or vice versa.. Journal of Clinical Oncology, 2015, 33, e20030-e20030.	0.8	0
25	High-risk ipilimumab-related diarrhea/colitis: Experience and use of ancillary tests in changing toxicity management.. Journal of Clinical Oncology, 2016, 34, e14552-e14552.	0.8	0
26	Association of response to programmed death 1 receptor or ligand (PD1/PDL1) blockade with immune-related gene expression profiling across three cancer-types.. Journal of Clinical Oncology, 2016, 34, 3038-3038.	0.8	0
27	Blood eosinophil counts as predictive marker in advanced melanoma patients treated with anti-PD1 therapies.. Journal of Clinical Oncology, 2017, 35, 66-66.	0.8	0
28	Clinical experience with rucaparib after prior PARPi treatment: A subanalysis from the rucaparib access program in Spain by GEICO.. Journal of Clinical Oncology, 2022, 40, e17598-e17598.	0.8	0
29	Clinical insights from the rucaparib access program in Spain: A sub-analysis of long-term responders by GEICO.. Journal of Clinical Oncology, 2022, 40, e17562-e17562.	0.8	0